Creative Medical Technology Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Creative Medical Technology Holdings, Inc. on April 4, 2017. The report addresses a specific corporate event occurring on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific event and does not contain financial statements.
Material Changes
On April 4, 2017, the Company issued a press release announcing the filing of a patent application. This application covers the use of the Company's AmnioStem Universal Donor stem cell product as a treatment for radiation toxicity.
Guidance, Outlook, and Risks
The press release furnished as Exhibit 99.1 contains forward-looking statements based on information available as of the date made. Management warns that actual results could differ materially due to various factors, including those discussed in the Annual Report on Form 10-K for the year ended December 31, 2016. The Company assumes no obligation to update these statements unless required by law.
Investor Verification Checklist
- Verify the status and scope of the patent application for AmnioStem Universal Donor regarding radiation toxicity.
- Review the full text of the press release provided in Exhibit 99.1.
- Consult the Annual Report on Form 10-K for the year ended December 31, 2016, for detailed risk factors.
- Confirm the Company's current financial position through recent 10-Q or 10-K filings, as this 8-K contains no financial data.